Alnylam Pharmaceuticals Inc (ALNY)vsHalozyme Therapeutics Inc (HALO)
ALNY
Alnylam Pharmaceuticals Inc
$303.05
-0.19%
HEALTHCARE · Cap: $37.76B
HALO
Halozyme Therapeutics Inc
$71.53
-0.10%
HEALTHCARE · Cap: $8.24B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 184% more annual revenue ($4.29B vs $1.51B). HALO leads profitability with a 23.1% profit margin vs 12.6%. HALO trades at a lower P/E of 24.4x. HALO earns a higher WallStSmart Score of 70/100 (B).
ALNY
Strong Buy65
out of 100
Grade: B-
HALO
Strong Buy70
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.4%
Fair Value
$2372.19
Current Price
$303.05
$2069.14 discount
Intrinsic value data unavailable for HALO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Every $100 of equity generates 159 in profit
Strong operational efficiency at 49.0%
Revenue surging 42.2% year-over-year
Keeps 23 of every $100 in revenue as profit
Earnings expanding 31.2% YoY
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 37.6x book value
Grey zone — moderate risk
Weak financial health signals
Trading at 38.7x book value
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : HALO
The strongest argument for HALO centers on Return on Equity, Operating Margin, Revenue Growth. Profitability is solid with margins at 23.1% and operating margin at 49.0%. Revenue growth of 42.2% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 70.9x leaves little room for execution misses.
Bear Case : HALO
The primary concerns for HALO are Altman Z-Score, Piotroski F-Score, Price/Book. Debt-to-equity of 9.76 is elevated, increasing financial risk.
Key Dynamics to Monitor
HALO carries more volatility with a beta of 0.87 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
HALO generates stronger free cash flow (176M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
HALO scores higher overall (70/100 vs 65/100), backed by strong 23.1% margins and 42.2% revenue growth. ALNY offers better value entry with a 86.4% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Halozyme Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?